Gasek Nathan, Zhou Albert E, Gronbeck Christian, Jain Neelesh P, Balboul Sarah, McMullan Patrick, Skudalski Lauren, Gulati Nicholas, Ungar Jonathan, Grant-Kels Jane M, Sloan Brett, Adalsteinsson Jonas A
Department of Dermatology, University of Connecticut School of Medicine, Farmington, CT, United States of America.
Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, United States of America.
J Am Acad Dermatol. 2025 Feb 21. doi: 10.1016/j.jaad.2024.10.130.
Advancements in the treatment of keratinocyte carcinoma have broadened therapeutic opportunities for patients who elect to avoid surgery or are poor surgical candidates. Due to this evolving landscape of pharmacologic (topical, intralesional or systemic), photodynamic, laser and radiation based, and minimally-invasive treatments (either field-directed, lesion-directed, and/or systemic), providers may be faced with uncertainty in selecting an optimal alternative to surgical care. Part 2 of this CME will outline established and emerging evidence-based treatment and preventive therapies for keratinocyte carcinoma to guide care for patients with surgical contraindications.
角质形成细胞癌治疗方法的进步为那些选择避免手术或手术风险较高的患者拓宽了治疗选择。由于药物治疗（局部、病灶内或全身用药）、光动力治疗、激光和放射治疗以及微创治疗（区域定向、病灶定向和/或全身治疗）不断发展，医疗服务提供者在选择手术治疗的最佳替代方案时可能会面临不确定性。本继续医学教育的第2部分将概述角质形成细胞癌已确立的和新出现的循证治疗及预防疗法，以指导手术禁忌患者的护理。
